Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tsumura & Co ( (JP:4540) ) has provided an update.
Tsumura & Co. has entered into a large unsecured syndicated loan agreement with a bank group led by MUFG Bank to finance active investment in equipment and business initiatives tied to its long-term management vision, including sustaining growth in its domestic operations and expanding its presence in China. The agreement, split into two tranches totaling ¥50 billion and maturing in 2033 and 2036, includes financial covenants requiring the company to maintain at least 75% of specified consolidated net asset levels and to avoid recording operating losses for two consecutive fiscal years, underscoring both the lender’s risk controls and the company’s commitment to financial discipline, although Tsumura says the deal will have no material impact on its current earnings outlook.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4226.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
More about Tsumura & Co
Tsumura & Co. is a Japanese pharmaceutical company listed on the Tokyo Stock Exchange Prime Market, best known for manufacturing and supplying Kampo (traditional Japanese herbal) medicines and related healthcare products. The company’s core business centers on its domestic pharmaceutical operations, with a strategic emphasis on stable growth in Japan and expansion in the Chinese market, reflecting its focus on both mature and high-growth Asian healthcare segments.
Average Trading Volume: 380,588
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen319.8B
For a thorough assessment of 4540 stock, go to TipRanks’ Stock Analysis page.